Treating hair loss with finasteride, dutasteride and minoxidil, as well as micro-needling, potentially using research chemicals such as Pyril and Senzu Beans.
Hair loss treatments, specifically 5AR inhibitors, can impact neurosteroids and sexual health. The effects of topical fin/dut on tissue-specific DHT levels are unclear.
A user's decision to shave their head after experiencing hair loss since the age of 17, and discussion around the potential use of Fin for treating hair loss.
Khalidsh1: Ok. I will upload one soon
This user has been using a combination of oral minoxidil and finasteride, as well as topical minoxidil to treat their hair loss over the past nine months with significant progress. They have also observed thickening in other areas such as eyelashes and eyebrows.
A 24 year old female experiencing rapid, unexplained hair loss over the course of two weeks and looking for advice. Treatments suggested include Rogaine, finasteride, minoxidil, RU58841, and seeing a dermatologist.
The conversation discusses a hair loss treatment regimen that includes a topical spray with finasteride and minoxidil, tretinoin, and using a Derminator (microneedling device) at 1.25mm depth every 5-6 days. The user reports positive results after 90 days and plans to continue the treatment, with others commenting on the process and potential outcomes.
The user's decision to shave their head rather than continue using drugs like finasteride and minoxidil to try and stop hair loss, as well as other suggestions such as scalp micropigmentation.
Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.
Treatments for hair loss, including topical dutasteride minoxidil, tretonin, dermarolling, serioxyl, and redensyl over a period of 3 months; switching from RU58841 to pyrilutamide was suggested with potentially less risk of systemic side effects; and encouragement to not give up hope.